Lenvatinib, sintilimab combined interventional treatment vs bevacizumab, sintilimab combined interventional treatment for intermediate-advanced unresectable hepatocellular carcinoma

Table 1 Baseline characteristics of the bevacizumab plus sintilimab plus interventional treatment and lenvatinib plus sintilimab plus interventional treatment groups before and after propensity score matching, n (%)

Variable	Before PSM			After PSM
	BeSiIT (n = 32)	LeSiIT (n = 95)	P value	BeSiIT (n = 28)	LeSiIT (n = 50)	P value
Age			1.000			0.835
< 65 years	24 (75.0)	70 (73.7)		21 (75.0)	35 (70.0)
≥ 65 years	8 (25.0)	25 (26.3)		7 (25.0)	15 (30.0)
Sex			0.663			0.916
Female	4 (12.5)	17 (17.9)		4 (14.3)	9 (18.0)
Male	28 (87.5)	78 (82.1)		24 (85.7)	41 (82.0)
Hepatitis			0.212			1.000
No	4 (12.5)	4 (4.2)		3 (10.7)	4 (8.0)
Yes	28 (87.5)	91 (95.8)		25 (89.3)	46 (92.0)
Liver cirrhosis			1.000			1.000
No	9 (28.1)	27 (28.4)		8 (28.6)	14 (28.0)
Yes	23 (71.9)	68 (71.6)		20 (71.4)	36 (72.0)
AFP, ng/mL			1.000			1.000
≤ 400	18 (56.2)	52 (54.7)		15 (53.6)	28 (56.0)
> 400	14 (43.8)	43 (45.3)		13 (46.4)	22 (44.0)
Tumor size, cm			0.532			0.689
≤ 10	20 (62.5)	67 (70.5)		17 (60.7)	34 (68.0)
> 10	12 (37.5)	28 (29.5)		11 (39.3)	16 (32.0)
Tumor number			0.021a			0.953
≤ 3	24 (75.0)	47 (49.5)		20 (71.4)	34 (68.0)
> 3	8 (25.0)	48 (50.5)		8 (28.6)	16 (32.0)
Child-Pugh			0.880			1.000
A	26 (81.2)	74 (77.9)		23 (82.1)	40 (80.0)
B	6 (18.8)	21 (22.1)		5 (17.9)	10 (20.0)
BCLC stage			0.130			0.984
B	8 (25.0)	40 (42.1)		7 (25.0)	14 (28.0)
C	24 (75.0)	55 (57.9)		21 (75.0)	36 (72.0)
ECOG PS			0.136			0.673
0	26 (81.2)	59 (62.1)		22 (78.6)	36 (72.0)
1	5 (15.6)	31 (32.6)		5 (17.9)	13 (26.0)
2	1 (3.1)	5 (5.3)		1 (3.6)	1 (2.0)
Metastasis			0.327			1.000
No	20 (62.5)	70 (73.7)		19 (67.9)	34 (68.0)
Yes	12 (37.5)	25 (26.3)		9 (32.1)	16 (32.0)
Vascular invasion			0.027a			0.417
No	12 (37.5)	59 (62.1)		10 (35.7)	24 (48.0)
Yes	20 (62.5)	36 (37.9)		18 (64.3)	26 (52.0)

^aP value < 0.05, and it is statistically significant.

PSM: Propensity score matching; BeSiIT: Bevacizumab plus sintilimab plus interventional treatment; LeSiIT: Lenvatinib plus sintilimab plus interventional treatment; AFP: Α-fetoprotein; BCLC: The Barcelona Clinic Liver Cancer; ECOG PS: Eastern Cooperative Oncology Group Performance Status.